Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2007 1
2011 2
2012 1
2013 3
2015 2
2017 1
2020 3
2021 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.
Redman MW, Papadimitrakopoulou VA, Minichiello K, Hirsch FR, Mack PC, Schwartz LH, Vokes E, Ramalingam S, Leighl N, Bradley J, Miao J, Moon J, Highleyman L, Miwa C, LeBlanc ML, Malik S, Miller VA, Sigal EV, Adam S, Wholley D, Sigman C, Smolich B, Blanke CD, Kelly K, Gandara DR, Herbst RS. Redman MW, et al. Among authors: sigal ev. Lancet Oncol. 2020 Dec;21(12):1589-1601. doi: 10.1016/S1470-2045(20)30475-7. Epub 2020 Oct 27. Lancet Oncol. 2020. PMID: 33125909 Free PMC article. Clinical Trial.
New drug approvals in oncology.
Kurzrock R, Kantarjian HM, Kesselheim AS, Sigal EV. Kurzrock R, et al. Among authors: sigal ev. Nat Rev Clin Oncol. 2020 Mar;17(3):140-146. doi: 10.1038/s41571-019-0313-2. Epub 2020 Feb 4. Nat Rev Clin Oncol. 2020. PMID: 32020042 Review.
Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP).
Vaidya R, Unger JM, Qian L, Minichiello K, Herbst RS, Gandara DR, Neal JW, Leal TA, Patel JD, Dragnev KH, Waqar SN, Edelman MJ, Sigal EV, Adam SJ, Malik S, Blanke CD, LeBlanc ML, Kelly K, Gray JE, Redman MW. Vaidya R, et al. Among authors: sigal ev. JCO Precis Oncol. 2023 Sep;7:e2300218. doi: 10.1200/PO.23.00218. JCO Precis Oncol. 2023. PMID: 37677122
Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I.
Unger JM, Qian L, Redman MW, Tavernier SS, Minasian L, Sigal EV, Papadimitrakopoulou VA, Leblanc M, Cleeland CS, Dzingle SA, Summers TJ, Chao H, Madhusudhana S, Villaruz L, Crawford J, Gray JE, Kelly KL, Gandara DR, Bazhenova L, Herbst RS, Gettinger SN, Moinpour CM. Unger JM, et al. Among authors: sigal ev. J Natl Cancer Inst. 2023 Apr 11;115(4):437-446. doi: 10.1093/jnci/djad003. J Natl Cancer Inst. 2023. PMID: 36625510 Free PMC article. Clinical Trial.
Adaptive licensing: taking the next step in the evolution of drug approval.
Eichler HG, Oye K, Baird LG, Abadie E, Brown J, Drum CL, Ferguson J, Garner S, Honig P, Hukkelhoven M, Lim JC, Lim R, Lumpkin MM, Neil G, O'Rourke B, Pezalla E, Shoda D, Seyfert-Margolis V, Sigal EV, Sobotka J, Tan D, Unger TF, Hirsch G. Eichler HG, et al. Among authors: sigal ev. Clin Pharmacol Ther. 2012 Mar;91(3):426-37. doi: 10.1038/clpt.2011.345. Epub 2012 Feb 15. Clin Pharmacol Ther. 2012. PMID: 22336591 Review.
The Value of Addressing Patient Preferences.
Allen JD, Stewart MD, Roberts SA, Sigal EV. Allen JD, et al. Among authors: sigal ev. Value Health. 2017 Feb;20(2):283-285. doi: 10.1016/j.jval.2016.11.029. Value Health. 2017. PMID: 28237210 Free article.
The 21st Century Cures Act.
McClellan MB, Sigal EV. McClellan MB, et al. Among authors: sigal ev. N Engl J Med. 2015 Oct 22;373(17):1677-8. doi: 10.1056/NEJMc1509640. N Engl J Med. 2015. PMID: 26488711 No abstract available.
Drug safety and drug efficacy: two sides of the same coin.
Young RC, Friedman MA, Schilsky RL, Sigal EV. Young RC, et al. Among authors: sigal ev. Clin Cancer Res. 2007 May 1;13(9):2533-4. doi: 10.1158/1078-0432.CCR-07-0608. Clin Cancer Res. 2007. PMID: 17473179 No abstract available.
Developing standards for breakthrough therapy designation in oncology.
Horning SJ, Haber DA, Selig WK, Ivy SP, Roberts SA, Allen JD, Sigal EV, Sawyers CL. Horning SJ, et al. Among authors: sigal ev. Clin Cancer Res. 2013 Aug 15;19(16):4297-304. doi: 10.1158/1078-0432.CCR-13-0523. Epub 2013 May 29. Clin Cancer Res. 2013. PMID: 23719260 Free PMC article.
18 results